Study guide

26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI

Key Takeaways Explain This Topic AI

The National Immunization Program gives BCG and hepatitis B at birth; pentavalent, bOPV and PCV at 6, 10 and 14 weeks; IPV at 14 weeks and 9 months; and a measles-containing vaccine at 9 and 12 months.

A fully immunized child has received BCG, three doses each of pentavalent vaccine and OPV, and two doses of a measles-containing vaccine before the first birthday.

School-based immunization gives measles-rubella and Td to Grade 1 and Grade 7 learners and HPV vaccine to girls aged 9 to 14.

Live vaccines are contraindicated in severe immunodeficiency and pregnancy; mild illness, low-grade fever, malnutrition, prematurity and antibiotics are not contraindications.

The VVM shows heat exposure (discard at stage 3 or 4), while the shake test detects freezing of adsorbed vaccines such as pentavalent, hepatitis B and PCV.

Last updated: October 2026

Why this area matters

The TOS asks you to prescribe the vaccines indicated at each age and apply well-child and preventive care. Philippine immunization coverage fell below target in recent years, and outbreaks of measles, diphtheria, pertussis and polio followed. In early 2025, partial data showed only about 61% of eligible children were fully immunized , against a 95% goal. Every visit, for any reason, is a chance to check and complete a child's vaccines and avoid "missed opportunities".

Statutory Framework: Republic Act No. 10152

Signed into law in 2011, Republic Act No. 10152 expanded the coverage of Presidential Decree No. 996 (the 1976 compulsory immunization decree) and mandated the provision of basic immunization services free of charge to all infants and children up to 5 years of age in all government hospitals, rural health units (RHUs), and barangay health centers. The Act expanded mandatory coverage to encompass:

  • Tuberculosis (BCG)
  • Hepatitis B
  • Diphtheria
  • Tetanus
  • Pertussis (Whooping Cough)
  • Poliomyelitis
  • Measles
  • Mumps
  • Rubella (German Measles)
  • Haemophilus influenzae type b (Hib)

Other vaccine-preventable diseases recommended by the Secretary of Health (such as Pneumococcal Conjugate Vaccine and Rotavirus Vaccine).

The Official Philippine DOH EPI Immunization Schedule

Every Filipino physician must memorize the precise timing, route, anatomical injection site, and minimum intervals governing the national immunization schedule.

The National EPI Schedule Table

Vaccine Designation Target Disease Protection Recommended Age at Administration Dose Volume Route of Administration Standard Anatomical Site

BCG Tuberculosis (meningitis and miliary TB) At birth (or earliest opportunity) 0.05 mL Intradermal (ID) Right deltoid region of the upper arm

Hepatitis B (Birth Dose) Perinatal Hepatitis B virus transmission At birth (within the first 24 hours ) 0.5 mL Intramuscular (IM) Anterolateral thigh ( vastus lateralis )

Pentavalent (DTP-HepB-Hib) Diphtheria, Tetanus, Pertussis, Hep B, Hib 6 weeks, 10 weeks, 14 weeks (3 doses at 4-week intervals) 0.5 mL Intramuscular (IM) Anterolateral thigh ( vastus lateralis )

bOPV (Oral Polio Vaccine) Poliomyelitis (Types 1 and 3) 6 weeks, 10 weeks, 14 weeks (3 doses at 4-week intervals) 2 drops Oral (PO) Directly onto the tongue

PCV (Pneumococcal Conjugate) S. pneumoniae invasive disease & pneumonia 6 weeks, 10 weeks, 14 weeks (3 primary doses) 0.5 mL Intramuscular (IM) Anterolateral thigh ( vastus lateralis )

IPV (Inactivated Polio Vaccine) Poliomyelitis (Types 1, 2, and 3 humoral IgG) 14 weeks (Dose 1) and 9 months (Dose 2) 0.5 mL Intramuscular (IM) Anterolateral thigh ( vastus lateralis )

Measles-containing vaccine (MMR, or MR) Measles, Mumps, and Rubella 9 months (dose 1) and 12 months (dose 2) 0.5 mL Subcutaneous (SC) Outer upper arm

  • Critical Clinical Details by Vaccine
  • 1. Bacille Calmette-Guérin (BCG)

Composition: Live attenuated strain of Mycobacterium bovis .

Dose & Technique: Exactly 0.05 mL intradermally using a 26- or 27-gauge tuberculin syringe over the right deltoid insertion. An immediate pale, blanched wheal (6-8 mm diameter) must appear.

Normal Reaction Timeline:

Immediate: pale blanched wheal that disappears within 30 minutes.

2 to 3 weeks: small, red, tender indurated papule develops.

4 to 6 weeks: papule ulcerates, secreting serous exudate.

8 to 12 weeks: ulcer heals spontaneously, leaving a permanent, depressed, 4-7 mm scar.

Counseling: Advise the caregiver never to squeeze the ulcer, apply alcohol, ointments, or compressive bandages.

Adverse Reactions: Local abscess formation (if injected subcutaneously rather than intradermally) and regional suppurative lymphadenitis (BCGitis).

2. Hepatitis B Vaccine (Birth Dose)

Composition: Recombinant hepatitis B surface antigen (HBsAg) produced in yeast cells.

Window of Efficacy: Must be administered within the first 24 hours of birth . When an infant is born to an HBsAg-positive mother, administration of Hepatitis B vaccine plus Hepatitis B Immune Globulin (HBIG 0.5 mL IM) at separate anatomical sites within 12 hours reduces perinatal transmission from 90% to < 5 % < 5\% < 5% .

3. Pentavalent Vaccine (DTwP-HepB-Hib)

Composition: Diphtheria toxoid, Tetanus toxoid, whole-cell killed Bordetella pertussis (wP), recombinant HBsAg, and Haemophilus influenzae type b polyribosylribitol phosphate (PRP) capsular polysaccharide conjugated to tetanus toxoid.

Administration: Three doses at 6, 10, and 14 weeks (minimum interval: 4 weeks). Whole-cell pertussis (wP) gives longer-lasting protection than acellular pertussis (aP) but causes more transient fever, local swelling and irritability.

4. Polio Vaccination: bOPV and IPV Dual Strategy

Rationale for Dual Strategy: Bivalent Oral Polio Vaccine (bOPV: Sabin types 1 and 3) induces potent intestinal secretory IgA immunity that halts environmental fecal-oral transmission. Inactivated Polio Vaccine (IPV: Salk trivalent killed types 1, 2, and 3) induces systemic serum IgG antibodies, providing lifelong neuroprotection against all three serotypes without any risk of Vaccine-Associated Paralytic Poliomyelitis (VAPP) or circulating Vaccine-Derived Polioviruses (cVDPV).

Schedule: Two doses of IPV are now standard in the Philippine EPI (administered at 14 weeks and 9 months).

5. Measles-Rubella (MR) and Measles-Mumps-Rubella (MMR)

Timing: Dose 1 at 9 months and Dose 2 at 12 months (MMR in the current NIP; MR has also been used). Two doses before the first birthday are part of the definition of a fully immunized child.

Why at 9 Months? Maternally transferred anti-measles IgG antibodies wane between 6 and 9 months. Vaccinating at 9 months seroconverts approximately 85% of infants; the second dose at 12 months seroconverts the remaining 15%, achieving > 95 − 97 % > 95-97\% > 95 − 97% population protection.

Biological Classification of Vaccines

Understanding the biological category determines handling requirements, immunologic mechanisms, and clinical contraindications.

Vaccine Category Mechanism & Characteristics Clinical Examples

Live Attenuated Organism is living but weakened; replicates in host, stimulating robust cellular (CD8+ T-cell) and humoral (IgG and secretory IgA) immunity. Usually single-dose efficacy. Fragile; sensitive to heat. Contraindicated in severe immunocompromise and pregnancy. BCG , OPV , MR , MMR , Rotavirus , Varicella , Yellow Fever.

Inactivated (Killed Whole) Organism is killed via heat or chemicals (formalin); cannot replicate. Requires multiple doses and adjuvants; stimulates predominantly humoral (serum IgG) immunity without mucosal IgA. Safe in immunocompromised hosts. IPV (Salk) , Whole-cell Pertussis (wP), Inactivated Influenza, Hepatitis A, Inactivated Rabies.

Toxoids Inactivated bacterial exotoxins that have lost toxicity but retain immunogenicity. Induces neutralizing antibodies against toxin, not the bacterium itself. Requires booster doses. Tetanus Toxoid (TT) , Diphtheria Toxoid (DT) .

Subunit / Recombinant / Conjugate Purified bacterial or viral fragments (capsular polysaccharides, surface antigens). Polysaccharide antigens conjugated to carrier proteins (tetanus or CRM197 diphtheria) convert T-cell-independent antigens to T-cell-dependent antigens , inducing immunologic memory in infants < 2 < 2 < 2 years. Hepatitis B (recombinant HBsAg), Hib (PRP conjugate), PCV (pneumococcal conjugate), HPV , Acellular Pertussis (aP).

Cold Chain Logistics and Vaccine Vial Monitors (VVM)

The cold chain is a temperature-controlled supply chain that ensures vaccine potency from manufacturer to the child's arm. Breaks in the cold chain result in permanent, irreversible loss of immunogenicity.

Temperature Storage Zones

Refrigerator Compartment (+2°C to +8°C):

Required for all freeze-sensitive adsorbed vaccines: Pentavalent (DTP-HepB-Hib) , PCV , Hepatitis B , IPV , and Td/TT .

Lyophilized vaccines with diluents: BCG (diluent must never be frozen; keep at + 2 ∘ C +2^\circ\text{C} + 2 ∘ C to + 8 ∘ C +8^\circ\text{C} + 8 ∘ C ).

Storage Rules: Vaccines must be placed on the central shelves, with spaces between boxes for air circulation. Never store vaccines in the door shelves (variable temperature) or directly against the rear cooling plate/evaporator.

Freezer Range (-15°C to -25°C):

Used at national and regional stores for freeze-tolerant vaccines: OPV and lyophilized measles-containing vaccines. At health-facility level, these are usually kept at +2°C to +8°C with the other vaccines, while freeze-sensitive vaccines must never be frozen.

The Vaccine Vial Monitor (VVM)

A Vaccine Vial Monitor (VVM) is a heat-sensitive chemical indicator consisting of a square inside a darker circle, printed on the vaccine vial label. As the vial is exposed to cumulative ambient heat over time, the inner square darkens.

VVM Stage Visual Appearance of Inner Square Clinical Action

Stage 1 Inner square is distinctly lighter than the outer circle. USE the vaccine (if expiration date has not passed).

Stage 2 Inner square is still lighter than the outer circle. USE the vaccine ; prioritize this vial to be used first.

Stage 3 Inner square matches the color of the outer circle (Cutoff Point). DO NOT USE the vaccine ; discard immediately. Potency compromised.

Stage 4 Inner square is darker than the outer circle. DO NOT USE the vaccine ; discard immediately. Severe heat exposure.

The Shake Test for Freeze Damage

Adsorbed vaccines (Pentavalent, Hepatitis B, PCV, Td) contain an aluminum adjuvant. Freezing causes the aluminum lattice to shatter and precipitate into large, heavy granules that rapidly fall out of suspension, destroying vaccine potency and increasing injection-site abscess formation.

Shake Test Procedure:

Take a vial from the suspected frozen batch and an intentionally frozen-and-thawed control vial of the same manufacturer and lot.

Shake both vials vigorously for 10 to 15 seconds simultaneously.

Place them side-by-side on a flat surface against a light background and observe the rate of sedimentation.

Positive Result (Freeze Damaged): If the suspected vial sediments rapidly and forms a clear supernatant fluid faster than or at the same rate as the control vial, the vaccine has been frozen and must be discarded .

Negative Result (Intact): If the suspected vial sediments very slowly and remains turbid and cloudy much longer than the control vial, the vaccine has not suffered freeze damage and is safe to use.

Contraindications vs. False Contraindications

In clinical practice and board examinations, distinguishing true contraindications from misconceptions is vital to prevent missed immunization opportunities.

True Absolute Contraindications

Severe Anaphylaxis: History of immediate, life-threatening anaphylactic reaction to a prior dose of the vaccine or an identical constituent (e.g., neomycin, gelatin, or yeast). Note: egg allergy is not a contraindication to MMR (MMR is grown in chick embryo fibroblast cultures, not egg albumen).

Encephalopathy within 7 Days of Pertussis Vaccine: Development of encephalopathy (coma, decreased consciousness, prolonged seizures) not attributable to another cause within 7 days of receiving DTwP or DTaP. Action: permanently discontinue the pertussis component; complete future vaccinations with DT or Td.

Severe Immunodeficiency for Live Vaccines: Congenital immunodeficiencies (SCID, agammaglobulinemia), leukemia, lymphoma, generalized malignancy, high-dose systemic immunosuppressive corticosteroid therapy ( > 2 mg/kg/day > 2\text{ mg/kg/day} > 2 mg/kg/day of prednisone for > 14 days > 14\text{ days} > 14 days ), and symptomatic HIV infection with severe CD4+ T-lymphocyte suppression prohibit BCG, OPV, MR, MMR, Varicella, and Rotavirus .

Valid Reasons to Temporarily Defer

Moderate to Severe Acute Febrile Illness: High fever or systemic prostration warrants deferral until acute illness resolves, to avoid confusing symptoms of the illness with vaccine adverse effects.

False Contraindications (DO NOT DEFER VACCINATION!)

Condition / Scenario Why Vaccination Must Proceed (Do Not Defer)

Mild acute illness (common cold, low-grade fever < 38.5 ∘ C < 38.5^\circ\text{C} < 38. 5 ∘ C , mild diarrhea) Does not impair antibody seroconversion or increase adverse event rates. Deferral results in missed coverage.

Current antibiotic or antimicrobial therapy Antibiotics do not interfere with viral vaccines or bacterial toxoids/killed vaccines (only oral typhoid Ty21a is affected).

Prematurity or low birth weight Preterm infants must be vaccinated according to their chronological age , not gestational age. Hepatitis B birth dose can be given at chronological birth (or at 2,000 g if clinically stable).

Malnutrition or underweight status Malnourished infants are at the highest risk of mortality from measles and pneumonia; immunization is urgently required.

History of simple febrile seizure Not a contraindication; pre-treat with antipyretics for comfort.

Breastfeeding Does not interfere with infant immune response to injected or oral vaccines.

Family history of sudden infant death syndrome (SIDS) or vaccine reactions Not a contraindication to any childhood vaccine.

Adverse Events Following Immunization (AEFI)

An Adverse Event Following Immunization (AEFI) is any untoward medical occurrence that follows immunization and does not necessarily have a causal relationship with the vaccine. The DOH Epidemiology Bureau manages national AEFI surveillance.

Classification of AEFI

Vaccine Product-Related Reaction: Caused by intrinsic biophysical properties of the vaccine (e.g., local injection-site soreness, low-grade fever after pertussis, transient rash 7-10 days after MMR).

Vaccine Quality Defect-Related Reaction: Caused by manufacturing defects (e.g., inadequate inactivation of endotoxin).

Immunization Error-Related (Programmatic) Reaction: Caused by improper handling, storage, reconstitution, or administration (e.g., sterile abscess from subcutaneous rather than intradermal BCG administration; bacterial sepsis from contaminated multidose vials).

Immunization Anxiety-Related Reaction: Arising from anxiety about the injection (e.g., vasovagal syncope, hyperventilation in adolescents).

Coincidental Event: Caused by an underlying condition that manifested coincidentally around the time of immunization.

Management of Post-Vaccination Anaphylaxis

Sudden onset of stridor, wheezing, hypotension, generalized urticaria, or facial angioedema within 5 to 30 minutes of vaccination.

First-Line Pharmacotherapy: Intramuscular Epinephrine (1:1,000 / 1 mg/mL) administered immediately into the anterolateral thigh.

Dose: 0.01 mg/kg (equivalent to 0.01 mL/kg of 1:1,000 solution; maximum single pediatric dose: 0.3 mg).

Repeat every 5 to 15 minutes PRN if symptoms persist.

Secondary agents: IV fluids for hypotension, nebulized albuterol for bronchospasm, and IV diphenhydramine/hydrocortisone as adjunctive therapy.

The fully immunized child and school-based immunization

A fully immunized child (FIC) has received by 12 months of age :

  • one dose of BCG;
  • three doses of pentavalent vaccine;
  • three doses of oral polio vaccine;

two doses of a measles-containing vaccine .

The hepatitis B birth dose and IPV are also given.

School-based immunization (DOH with DepEd):

measles-rubella (MR) and tetanus-diphtheria (Td) for Grade 1 and Grade 7 learners;

HPV vaccine for girls aged 9 to 14 , usually in Grade 4.

Supplemental immunization activities (mass campaigns) are held during outbreaks or to close immunity gaps, for example measles-rubella and polio campaigns.

Catch-up rules:

  • never restart a series;
  • continue from where it stopped, respecting minimum ages and intervals;

two live injectable vaccines are given the same day or at least 4 weeks apart.

Other recommended vaccines

The Philippine Pediatric Society and the Pediatric Infectious Disease Society of the Philippines publish a yearly childhood immunization calendar. It includes vaccines given routinely in private practice beyond the NIP:

  • rotavirus (oral, from 6 weeks; the series is completed by 8 months);
  • influenza , yearly from 6 months, with two doses 4 weeks apart the first time for children under 9;
  • varicella (from 12 months);
  • hepatitis A (from 12 months);
  • Japanese encephalitis (from 9 months);
  • typhoid (conjugate vaccine from 6 months);

meningococcal , HPV for boys and girls, and Tdap boosters.

Special groups (immunocompromised children, asplenia, travel) need additional or modified vaccines.

Loading diagram... Vaccine Cold Chain, VVM Decision Tree and Shake Test Protocol